After Over Two Years of Legal and Regulatory Battles, Abattis & its Management Receive Vindication Vancouver, British Columbia /March19, 2021/[...]

June 20, 2020    |    Abattis Bioceuticals VANCOUVER, BRITISH COLUMBIA / June 17, 2020 / Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide a comprehensive corporate and operational update.

Nov 8, 2019    |    Abattis Bioceuticals VANCOUVER, BRITISH COLUMBIA / Nov 8th, 2019 / Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) November 8, 2019 / Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) announces the following updates on recent developments related to Abattis since the trading of the Company’s common shares on the Canadian Stock Exchange (the “CSE”) was halted on February 4, 2019 (the “Halt”).

May 21, 2019    |    Abattis Bioceuticals VANCOUVER, BRITISH COLUMBIA / May 21st, 2019 / Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”).

VANCOUVER, BRITISH COLUMBIA / January 17, 2019 / Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis.